Should You Consider Buying Aurora Cannabis?

Aurora Cannabis (ACB) is one of the few cannabis companies that has lost more than half of its market capitalization this year. As of Monday, Aurora Cannabis was trading at 1.29 Canadian dollars—a fall of 53.8% so far this year. Last year, the stock lost 58.8% of its stock value. Currently, the company is trading 48.3% higher than its 52-week low of 0.87 Canadian dollars and 89.8% lower than its 52-week high of 12.62 Canadian dollars. So, should you consider buying Aurora Cannabis? Let’s look at analysts’ recommendations…

Analysts’ recommendations for Aurora Cannabis

On Monday, Brian Acker of Acker Finlay stated that he wouldn’t buy Aurora Cannabis, as reported by Cantech Letter. On BNN Bloomberg’s “Market Call” program, he stated that cannabis companies had a market capitalization of 100 billion dollars during their peak. Now, they have fallen to a fraction of that level. Acker is concerned that not many cannabis companies have become profitable yet. He thinks that it’s an opportunity to buy good quality stocks, which are available at discounts.

On Aurora Cannabis, Acker said, “Why would you look at a piece of crap like this, really? So forget Aurora, there’s so many other good things out there to look at and buy and make money on with a hell of a lot less risk than this one. So forget about it move on. This is an opportunity of really upgrading the quality of your portfolio and. And that’s what you should do.”

Since Aurora Cannabis reported its second-quarter earnings on February 14, Canaccord Genuity, CIBC, Cowen, Bryan Garnier, and MKM Partners have all lowered their target prices. Cowen also downgraded the stock from “neutral” to “sell.” As of Monday, 18 analysts cover the company. Among the analysts, 12 recommend a “hold,” one recommends a “buy,” and five recommend a “sell.” On the same day, analysts’ consensus target price was 1.86 Canadian dollars. The target price represents a 12-month return potential of 44.1%.

Valuation multiple

The decline in Aurora Cannabis’s stock price has also lowered its valuation multiple. As of Monday, Aurora Cannabis was trading at a forward EV-to-sales multiple of 5.0x. So far, the multiple has declined compared to 6.6x at the beginning of this year. As of Monday, Aurora Cannabis was trading at a premium compared to Aphria (NYSE:APHA) and HEXO (TSE:HEXO). They were trading at 1.7x and 2.4x, respectively. Meanwhile, Canopy Growth (TSE:WEED) was trading at a forward EV-to-sales multiple of 8.2x on the same day.

My take on Aurora Cannabis

By the end of the second quarter, Aurora Cannabis had 156 million in cash left, which excludes…

Continue reading at MARKETREALIST.com

 

You May Also Like

About the Author: admin

Leave a Reply

Your email address will not be published.